Braverman, J. (Julia)

Filtering

20231

Settings

Author search.filters.isAuthorOfPublication.30b8e061-2bf8-4fa3-8dbf-10d1d47b4411

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
    (2023) Delforge, M. (M.); Dhanda, D.S. (Devender S.); Shah, N. (Nina); Miera, M. (Matthew); Devlen, J. (Jennifer); Moshkovich, O. (Olga); Rodriguez-Otero, P. (Paula); Campbell, T.B. (Timothy B.); Munshi, N.C. (Nikhil C.); Gerould, H. (Heather); Braverman, J. (Julia); Lanar, S. (Sally)
    Objective: To understand the long-term experience of patients receiving ide-cel chimeric antigen receptor T (CAR T) cell therapy for relapsed or refractory multiple myeloma in the pivotal phase 2 KarMMa trial.Methods: This qualitative study analyzed semi-structured patient interviews 6-24 months after ide-cel infusion. Thematic analysis with quantitative and longitudinal analyses explored patient perceptions of ide-cel treatment experience, advantages and disadvantages, and long-term health-related quality of life impact. Patient journeys were developed from narrative analysis of perceived treatment benefits with known remission length.Results: Interviews with 45 patients 6-24 months postinfusion were analyzed; all reported >= 1 ide-cel treatment advantage, most often related to efficacy (n = 42/45, 93%), few or no side effects (n = 35/45, 78%), and avoidance of other treatments (n = 34/45, 76%). Patients generally reported 6-month improvements in physical health, functioning, emotional well-being, social life, and outlook on the future; these improvements mostly remained stable through 18 and 24 months. The most common patient journeys comprised physical, func-tioning, or emotional benefit with remission < 2 years.Conclusions: Longitudinal analysis of patient experiences showed sustained benefits and preference for ide-cel up to 24 months after treatment.Trial Registration Number and Date: NCT03361748. December 5, 2017.